Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents: Initial experiences in Japan

Yasufumi Kijima, Teiji Akagi, Koji Nakagawa, Manabu Taniguchi, Akira Ueoka, Kentaro Deguchi, Norihisa Toh, Hiroki Oe, Kengo Kusano, Shunji Sano, Hiroshi Itoh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although numerous studies have shown an association between a patent foramen ovale (PFO) and cryptogenic cerebrovascular accidents (CVA), there has been no definitive control study that demonstrated the benefit of percutaneous device closure of a PFO compared to medical therapy in patients with CVA. Additionally, few clinical data exist for Japanese patients in this field. We demonstrate the initial experiences in catheter closure of a PFO as secondary prevention of CVA in Japan. Catheter closure of a PFO was attempted in 7 patients who were diagnosed with cryptogenic CVA. Mean age at the procedure was 54 ± 19 years. The presence of spontaneous interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography without Valsalva maneuver in all of the patients. Amplatzer Cribriform device (n = 4) or Amplatzer PFO Occluder (n = 3) was used for the procedure and was successfully deployed. Device-related complications were not observed at the time of the procedure or during the follow-up period (mean period of 16 ± 9 months). Catheter closure of a PFO could be safely performed with Amplatzer Cribriform or Amplatzer PFO Occluder. This procedure may contribute to prevention of recurrent cryptogenic CVA in Japanese patients.

Original languageEnglish
Pages (from-to)11-17
Number of pages7
JournalCardiovascular Intervention and Therapeutics
Volume29
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Patent Foramen Ovale
Japan
Catheters
Stroke
Equipment and Supplies
Valsalva Maneuver
Transesophageal Echocardiography
Secondary Prevention
Echocardiography

Keywords

  • Catheter intervention
  • Cryptogenic stroke
  • Patent foramen ovale
  • Prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents : Initial experiences in Japan. / Kijima, Yasufumi; Akagi, Teiji; Nakagawa, Koji; Taniguchi, Manabu; Ueoka, Akira; Deguchi, Kentaro; Toh, Norihisa; Oe, Hiroki; Kusano, Kengo; Sano, Shunji; Itoh, Hiroshi.

In: Cardiovascular Intervention and Therapeutics, Vol. 29, No. 1, 2014, p. 11-17.

Research output: Contribution to journalArticle

Kijima, Yasufumi ; Akagi, Teiji ; Nakagawa, Koji ; Taniguchi, Manabu ; Ueoka, Akira ; Deguchi, Kentaro ; Toh, Norihisa ; Oe, Hiroki ; Kusano, Kengo ; Sano, Shunji ; Itoh, Hiroshi. / Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents : Initial experiences in Japan. In: Cardiovascular Intervention and Therapeutics. 2014 ; Vol. 29, No. 1. pp. 11-17.
@article{35a147259add4f52be518129f4ea7ada,
title = "Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents: Initial experiences in Japan",
abstract = "Although numerous studies have shown an association between a patent foramen ovale (PFO) and cryptogenic cerebrovascular accidents (CVA), there has been no definitive control study that demonstrated the benefit of percutaneous device closure of a PFO compared to medical therapy in patients with CVA. Additionally, few clinical data exist for Japanese patients in this field. We demonstrate the initial experiences in catheter closure of a PFO as secondary prevention of CVA in Japan. Catheter closure of a PFO was attempted in 7 patients who were diagnosed with cryptogenic CVA. Mean age at the procedure was 54 ± 19 years. The presence of spontaneous interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography without Valsalva maneuver in all of the patients. Amplatzer Cribriform device (n = 4) or Amplatzer PFO Occluder (n = 3) was used for the procedure and was successfully deployed. Device-related complications were not observed at the time of the procedure or during the follow-up period (mean period of 16 ± 9 months). Catheter closure of a PFO could be safely performed with Amplatzer Cribriform or Amplatzer PFO Occluder. This procedure may contribute to prevention of recurrent cryptogenic CVA in Japanese patients.",
keywords = "Catheter intervention, Cryptogenic stroke, Patent foramen ovale, Prevention",
author = "Yasufumi Kijima and Teiji Akagi and Koji Nakagawa and Manabu Taniguchi and Akira Ueoka and Kentaro Deguchi and Norihisa Toh and Hiroki Oe and Kengo Kusano and Shunji Sano and Hiroshi Itoh",
year = "2014",
doi = "10.1007/s12928-013-0193-9",
language = "English",
volume = "29",
pages = "11--17",
journal = "Cardiovascular Intervention and Therapeutics",
issn = "1868-4300",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents

T2 - Initial experiences in Japan

AU - Kijima, Yasufumi

AU - Akagi, Teiji

AU - Nakagawa, Koji

AU - Taniguchi, Manabu

AU - Ueoka, Akira

AU - Deguchi, Kentaro

AU - Toh, Norihisa

AU - Oe, Hiroki

AU - Kusano, Kengo

AU - Sano, Shunji

AU - Itoh, Hiroshi

PY - 2014

Y1 - 2014

N2 - Although numerous studies have shown an association between a patent foramen ovale (PFO) and cryptogenic cerebrovascular accidents (CVA), there has been no definitive control study that demonstrated the benefit of percutaneous device closure of a PFO compared to medical therapy in patients with CVA. Additionally, few clinical data exist for Japanese patients in this field. We demonstrate the initial experiences in catheter closure of a PFO as secondary prevention of CVA in Japan. Catheter closure of a PFO was attempted in 7 patients who were diagnosed with cryptogenic CVA. Mean age at the procedure was 54 ± 19 years. The presence of spontaneous interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography without Valsalva maneuver in all of the patients. Amplatzer Cribriform device (n = 4) or Amplatzer PFO Occluder (n = 3) was used for the procedure and was successfully deployed. Device-related complications were not observed at the time of the procedure or during the follow-up period (mean period of 16 ± 9 months). Catheter closure of a PFO could be safely performed with Amplatzer Cribriform or Amplatzer PFO Occluder. This procedure may contribute to prevention of recurrent cryptogenic CVA in Japanese patients.

AB - Although numerous studies have shown an association between a patent foramen ovale (PFO) and cryptogenic cerebrovascular accidents (CVA), there has been no definitive control study that demonstrated the benefit of percutaneous device closure of a PFO compared to medical therapy in patients with CVA. Additionally, few clinical data exist for Japanese patients in this field. We demonstrate the initial experiences in catheter closure of a PFO as secondary prevention of CVA in Japan. Catheter closure of a PFO was attempted in 7 patients who were diagnosed with cryptogenic CVA. Mean age at the procedure was 54 ± 19 years. The presence of spontaneous interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography without Valsalva maneuver in all of the patients. Amplatzer Cribriform device (n = 4) or Amplatzer PFO Occluder (n = 3) was used for the procedure and was successfully deployed. Device-related complications were not observed at the time of the procedure or during the follow-up period (mean period of 16 ± 9 months). Catheter closure of a PFO could be safely performed with Amplatzer Cribriform or Amplatzer PFO Occluder. This procedure may contribute to prevention of recurrent cryptogenic CVA in Japanese patients.

KW - Catheter intervention

KW - Cryptogenic stroke

KW - Patent foramen ovale

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84892845211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892845211&partnerID=8YFLogxK

U2 - 10.1007/s12928-013-0193-9

DO - 10.1007/s12928-013-0193-9

M3 - Article

C2 - 23824518

AN - SCOPUS:84892845211

VL - 29

SP - 11

EP - 17

JO - Cardiovascular Intervention and Therapeutics

JF - Cardiovascular Intervention and Therapeutics

SN - 1868-4300

IS - 1

ER -